HIV Envelope Protein gp120
"HIV Envelope Protein gp120" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
Descriptor ID |
D015699
|
MeSH Number(s) |
D12.776.964.775.325.164.249 D12.776.964.775.562.500.500 D12.776.964.970.880.325.164.249 D23.050.327.520.350
|
Concept/Terms |
HIV Envelope Protein gp120- HIV Envelope Protein gp120
- Envelope Glycoprotein gp120, HIV
- gp120 Envelope Glycoprotein, HIV
- HIV Envelope Glycoprotein gp120
- HTLV-III gp120
- HTLV III gp120
- gp120, HTLV-III
- env Protein gp120, HIV
- gp120(HIV)
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp120".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp120".
This graph shows the total number of publications written about "HIV Envelope Protein gp120" by people in this website by year, and whether "HIV Envelope Protein gp120" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 1 | 1 | 2 |
2004 | 1 | 0 | 1 |
2006 | 2 | 0 | 2 |
2010 | 2 | 1 | 3 |
2011 | 1 | 0 | 1 |
2016 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Envelope Protein gp120" by people in Profiles.
-
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021 10; 27(10):1718-1724.
-
The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. J Virol. 2016 Dec 01; 90(23):10642-10659.
-
Long antibody HCDR3s from HIV-na?ve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4446-51.
-
V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1. J Acquir Immune Defic Syndr. 2016 Mar 01; 71(3):237-45.
-
HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology. 2014 Dec; 471-473:81-92.
-
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13540-5.
-
Isobaric tagging-based quantification by mass spectrometry of differentially regulated proteins in synaptosomes of HIV/gp120 transgenic mice: implications for HIV-associated neurodegeneration. Exp Neurol. 2012 Aug; 236(2):298-306.
-
Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine. 2011 Dec 09; 30(1):78-94.
-
Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog. 2011 Sep; 7(9):e1002234.
-
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011 Sep 16; 333(6049):1633-7.